Literature DB >> 28815804

Octadentate Picolinic Acid-Based Bispidine Ligand for Radiometal Ions.

Peter Comba1, Una Jermilova2, Chris Orvig3, Brian O Patrick3, Caterina F Ramogida2, Katharina Rück1, Christina Schneider1, Miriam Starke1.   

Abstract

The synthesis of the octadentate bispidine ligand bearing two picolinic acid pendant arms (H2 bispa2 ), and its coordination chemistry with radionuclides relevant for nuclear medicine, namely indium(III) (111 In), lutetium(III) (177 Lu), and lanthanum(III) (as surrogate for 225 Ac), are reported. The non-radioactive metal complexes of the N6 O2 -type bispa ligand were characterized by 1 H and 13 C NMR spectroscopy, elemental analysis, mass spectrometry and single-crystal X-ray analysis. Experimental structural data, computational analysis, complex stabilities determined by potentiometric titration, and "radiostabilities" determined by competition studies in the presence of human serum reveal complex stabilities of H2 bispa2 comparable to those of the macrocyclic "gold standard" DOTA. After an incubation time of 1 day, 86 and 87 % of [177 Lu(bispa2 )]+ and [177 Lu(DOTA)]- , respectively, remain intact. Importantly, unlike DOTA, H2 bispa2 is radiolabeled quantitatively with 111 InIII and 225 AcIII under ambient conditions, which is an essential aspect when working with heat-sensitive antibodies as targeting vectors. In the case of 111 InIII , room temperature radiolabeling of H2 bispa2 yields molar activities as high as 70 MBq nmol-1 within 10 minutes. These are promising results for radiopharmaceutical applications of H2 bispa2 .
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  actinides; indium; lanthanides; radiolabeling; radiometals

Year:  2017        PMID: 28815804     DOI: 10.1002/chem.201702284

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  12 in total

1.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

2.  H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy.

Authors:  Karthika J Kadassery; A Paden King; Stanley Fayn; Kwamena E Baidoo; Samantha N MacMillan; Freddy E Escorcia; Justin J Wilson
Journal:  Bioconjug Chem       Date:  2022-06-07       Impact factor: 6.069

3.  Development of a multi faceted platform containing a tetrazine, fluorophore and chelator: synthesis, characterization, radiolabeling, and immuno-SPECT imaging.

Authors:  Anthony W McDonagh; Brooke L McNeil; Julie Rousseau; Ryan J Roberts; Helen Merkens; Hua Yang; François Bénard; Caterina F Ramogida
Journal:  EJNMMI Radiopharm Chem       Date:  2022-06-06

Review 4.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

5.  Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review.

Authors:  Hua Yang; Justin J Wilson; Chris Orvig; Yawen Li; D Scott Wilbur; Caterina F Ramogida; Valery Radchenko; Paul Schaffer
Journal:  J Nucl Med       Date:  2021-09-09       Impact factor: 11.082

6.  First-Generation Bispidine Chelators for 213 BiIII Radiopharmaceutical Applications.

Authors:  Frank Bruchertseifer; Peter Comba; Bodo Martin; Alfred Morgenstern; Johannes Notni; Miriam Starke; Hubert Wadepohl
Journal:  ChemMedChem       Date:  2020-07-02       Impact factor: 3.466

Review 7.  Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives.

Authors:  Manja Kubeil; Irma Ivette Santana Martínez; Michael Bachmann; Klaus Kopka; Kellie L Tuck; Holger Stephan
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-31

8.  Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac.

Authors:  Caterina F Ramogida; Andrew K H Robertson; Una Jermilova; Chengcheng Zhang; Hua Yang; Peter Kunz; Jens Lassen; Ivica Bratanovic; Victoria Brown; Lily Southcott; Cristina Rodríguez-Rodríguez; Valery Radchenko; François Bénard; Chris Orvig; Paul Schaffer
Journal:  EJNMMI Radiopharm Chem       Date:  2019-08-06

9.  Sensing Zn2+ in Aqueous Solution with a Fluorescent Scorpiand Macrocyclic Ligand Decorated with an Anthracene Bearing Tail.

Authors:  Matteo Savastano; Matteo Fiaschi; Giovanni Ferraro; Paola Gratteri; Palma Mariani; Antonio Bianchi; Carla Bazzicalupi
Journal:  Molecules       Date:  2020-03-17       Impact factor: 4.411

10.  Versatile Bispidine-Based Bifunctional Chelators for 64 CuII -Labelling of Biomolecules.

Authors:  Garima Singh; Kristof Zarschler; Sebastian Hunoldt; Irma Ivette Santana Martínez; Carmen L Ruehl; Madlen Matterna; Ralf Bergmann; Domokos Máthé; Nikolett Hegedüs; Michael Bachmann; Peter Comba; Holger Stephan
Journal:  Chemistry       Date:  2020-01-09       Impact factor: 5.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.